• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2020.15047

Activity of the antimicrobial peptide in children with cystic fibrosis

[Cystic fibrosis]
Elena Kestutisovna Zhekaite; Leonid Klimov; Svetlana Dolbnya; Elena Ivanovna Kondratieva; Natalia Anatolievna Ilyenkova; Victoria Kuryaninova; Vladimir Viktorovich Chikunov; Elena Alexandrovna Enina;

100 patients with cystic fibrosis aged 0 to 18 years and 58 healthy children were examined in Moscow, Krasnoyarsk and Stavropol. The concentration of α-1-3-defensin (HNP1-3), cathelicidin (LL-37), and calcidiol in the blood serum was determined in all patients. A significant deterioration in the availability of vitamin D was revealed as children grow. It was shown that the level of HNP1-3 above 4270 pg/ml is detected significantly more often in adolescents and, conversely, in the group of patients younger than 3 years, the level of HNP1-3 less than 2980 pg/ml is determined more often than in older children (χ2 test, p=0.008). The activity of LL-37 is almost the same in all age groups. Patients with cystic fibrosis are characterized by significantly lower serum calcidiol levels –25.1 [16.6–38.6] ng/ml than healthy children 31.7 [23.3–42.7] ng/ml (p=0.003). Moreover, the level of HNP1-3 below 2980 pg/ml was significantly more often detected among healthy children – 28 (48.3 %) than in patients with CF – 26 (26.0 %; p = 0.017). A weak relationship was revealed between the level of vitamin D and LL-37 r=0.278, p=0.001. Patients with CF are characterized by an increase in LL-37 in chronic Pseudomonas aeruginosa infection, for HNP1-3 such a relationship is not obtained.

Download

References:
1. Kapranov N. I., Kashirskya N. Yu. Cystic fibrosis. М.: «Medpraktica-М», 2014. (In Russ.).
2. National consensus «Cystic fibrosis: definition, diagnostic criteria, therapy» (Coordinators: Kapranov N., Kondratieva E., Kashirskaya N.). Meditsinskaya genetika. – Medical Genetics. 2016;11:108-109. (In Russ.).
3. Kapranov N. I., Kashirskaya N. Yu., Sherman V. D., Voronkova A. Yu., Shabalova L. A. [et al.]. Cystic fibrosis: current advances and current problems: guidelines. Moscow, 2011. (In Russ.).
4. Döring G., Hoiby N. Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cyst. Fibros. 2004;3(2):67-91. https://doi.org/10.1016/j.jcf.2004.03.008
5. Kondratyeva E. I., Yankina G. N., Tarasenko N. V., Loshkova E. V. The role of cytokines interleukin-1 family in formation cystic fibrosis and its complications. Kubansky nauchny meditsinsky vestnik. – Kuban Scientific Medical Bulletin. 2011;6(129):77-82. (In Russ.).
6. Shaginyan I. A., Kapranov N. I., Chernukha M. Yu., Alekseeva G. V., Semykin S. Yu. [et al.]. Microbial landscape of the lower respiratory tract in various age groups of children with cystic fibrosis. Zhurnal mikrobiologii, epidemiologii i immunobiologii. – Journal of Microbiology, Epidemiology and Immunobiology. 2010;1:15-20. (In Russ.).
7. Hauser A. R., Jain M., Bar-Meir M., McColley S. A. Microbes and outcomes in cystic fibrosis. Clin. Microbiol. Rev. 2011;24:1-70. https://doi.org/10.1128/CMR.00036-10
8. Smyth A. R., Bell S. C., Bojcin S., Bryon M., Duff A. [et al.]. European Cystic Fibrosis Society Standards of Care: Best practice guidelines. J. Cyst. Fibros. 2014;13(Suppl. 1):23- 42. https://doi.org/10.1016/j.jcf.2014.03.010
9. Kokryakov V. N., Kovalchuk L. V., Aleshina G. M., Shamova О. V. Cationic antimicrobial peptides as molecular immunity factors: multi-functionality. Zhurnal mikrobiologii, epidemiologii i immunobiologii. – Journal of microbiology, Epidemiology and Immunobiology. 2006;2:98-105. (In Russ.).
10. Nakatsuji T., Gallo R. L. Antimicrobial peptides: old molecules with new ideas. J. Invest. Dermatol. 2012;132(3Pt2):887- 895. https://doi.org/10.1038/jid.2011.387
11. Budikhina A. S., Pinegin B. V. Defensins – multifunctional cations peptides of human. Immunopatologiya, allergologiya, infektologiya. – Immunopathology, Allergology, Infectology. 2008;2:31-40. (In Russ.).
12. Schneider J. J., Unholzer A., Schaller M., Schäfer-Korting M., Korting H. C. Human defensins. J. Mol. Med. (Berl). 2005;83(8):587-595. https://doi.org/10.1007/s00109-005-0657-1
13. van Wetering S., Mannesse-Lazeroms S. P., van Sterkenburg M. A., Hiemstra P. S. Neutrophil defensins stimulate the release of cytokines by airway epithelial cells: modulation by dexamethasone. Inflamm. Res. 2002;51(1):8-15. https://doi.org/10.1007/pl00000282
14. Weiner D. J., Bucki R., Janmey P. A. The Antimicrobial Activity of the Cathelicidin LL37 Is Inhibited by F-actin Bundles and Restored by Gelsolin. Am. J. Respir. Cell. Mol. Biol. 2003;28(6):738-745. https://doi.org/10,1165/rcmb.2002-0191OC
15. Belyaeva I. V., Nikolaev A. V., Churilov L. P., Yablonskij P. K. Katelitsidins, vitamin D and tuberculosis. Vestnik Sankt-Peterburgskogo universiteta. – Bulletin of St. Petersburg University. 2013;3:3-18. (In Russ.).
16. Shaginyan I. A., Chernukha M. Yu., Kapranov N. I., Kondratyieva E. I., Kashirskaya N. Yu. [et al.]. Consensus «Cystic Fibrosis: definition, diagnostic criteria, treatment». Pediatr. – Pediatrician (St. Petersburg). 2016;8(1):80-96. (In Russ.).
17. Miller M. R., Hankinson J., Brusasco V., Burgos F., Casaburi R. [et al.]. Standardisation of spirometry. Eur. Respir. J. 2005;26:319-338. https://doi.org/10,1183/09031936.05.00034805
18. Pellegrino R., Viegi G., Brusasco V., Crapo R. O., Burgos F. [et al.]. Interpretative strategies for lung function tests. Eur. Respir. J. 2005;26:511-522. https://doi.org/10.1183/09031936.05.00035205
19. http://www.who.int/childgrowth/software/en/ WHO Anthroplus http://www.who.int/growthref/tools/en/
20. Hall W. B., Sparks A. A., Aris R. M. Vitamin D Deficiency in Cystic Fibrosis. Int. J. Endocrinol. 2010:218691. https://doi.org/10.1155/2010/218691
21. National program «Vitamin D deficiency in children and adolescents of the Russian Federation: modern approaches to correction». Union of Pediatricians of Russia [et al.]. M.: Pediatr, 2018. (In Russ.).
22. Lezhenko G. O., Abaturov O. Ye., Pashkova O. Ye., Pantyushenko L. I. Pathogenetic significance of antimicrobial peptides in the implementation of antibacterial protection in children with cystic fibrosis. Child health. 2013;3(46):44- 49.
23. Dai Q., Morita Y., Huang Y., Liaw P. C., Wu J. [et al.]. Modulation of Human Neutrophil Peptides on P. aeruginosa Killing, Epithelial Cell Inflammation and Mesenchymal Stromal Cell Secretome Profiles. J. Inflamm. Res. 2019;12:335-343. https://doi.org/10.2147/JIR.S219276

Keywords: cystic fibrosis, antimicrobial peptides, cathelicidin, α-1-3-defensins, Pseudomonas aeruginosa, lung function, vitamin D